Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
STTK Stock Forecast 2026-2027
$4.73
Current Price
$299.31M
Market Cap
Buy 4
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to STTK Price Targets
+26.8%
To High Target of $6.00
-15.4%
To Median Target of $4.00
-15.4%
To Low Target of $4.00
STTK Price Momentum
+1.9%
1 Week Change
+54.6%
1 Month Change
+297.5%
1 Year Change
+29.6%
Year-to-Date Change
-3.3%
From 52W High of $4.89
+583.5%
From 52W Low of $0.69
📊 TOP ANALYST CALLS
Did STTK Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Shattuck Labs is one of their latest high-conviction picks.
Latest STTK Stock Price Targets & Analyst Predictions
Based on our analysis of 8 Wall Street analysts, STTK has a bullish consensus with a median price target of $4.00 (ranging from $4.00 to $6.00). The overall analyst rating is Strong Buy (8.7/10). Currently trading at $4.73, the median forecast implies a -15.4% downside. This outlook is supported by 4 Buy, 2 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Joseph Pantginis at HC Wainwright & Co., projecting a 26.8% upside. Conversely, the most conservative target is provided by Yigal Nochomovitz at Citigroup, suggesting a 15.4% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
STTK Analyst Ratings
4
Buy
2
Hold
0
Sell
STTK Price Target Range
Low
$4.00
Average
$4.00
High
$6.00
Current: $4.73
Latest STTK Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for STTK.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jan 6, 2026 | Citigroup | Yigal Nochomovitz | Neutral | Maintains | $4.00 |
| Dec 1, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Upgrade | $6.00 |
| Sep 8, 2025 | Wedbush | David Nierengarten | Outperform | Initiates | $4.00 |
| Aug 14, 2025 | Leerink Partners | Faisal Khurshid | Outperform | Maintains | $2.00 |
| Aug 14, 2025 | Needham | James Ricchiuti | Hold | Reiterates | $N/A |
| Mar 27, 2025 | HC Wainwright & Co. | Joseph Pantginis | Neutral | Reiterates | $N/A |
| Mar 27, 2025 | Needham | Gil Blum | Hold | Reiterates | $N/A |
| Mar 17, 2025 | Leerink Partners | Faisal Khurshid | Outperform | Initiates | $4.00 |
| Nov 15, 2024 | HC Wainwright & Co. | Joseph Pantginis | Neutral | Reiterates | $N/A |
| Nov 14, 2024 | Needham | Gil Blum | Hold | Reiterates | $N/A |
| Oct 2, 2024 | Citigroup | Yigal Nochomovitz | Neutral | Downgrade | $2.00 |
| Oct 2, 2024 | Needham | Gil Blum | Hold | Downgrade | $8.00 |
| Oct 1, 2024 | HC Wainwright & Co. | Joseph Pantginis | Neutral | Downgrade | $N/A |
| Aug 27, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $16.00 |
| Aug 15, 2024 | Citigroup | Yigal Nochomovitz | Buy | Maintains | $8.00 |
| Aug 2, 2024 | Needham | Gil Blum | Buy | Reiterates | $8.00 |
| Aug 2, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $16.00 |
| Jun 20, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Maintains | $16.00 |
| Jun 17, 2024 | Citigroup | Yigal Nochomovitz | Buy | Maintains | $9.00 |
| Jun 14, 2024 | Needham | Gil Blum | Buy | Maintains | $8.00 |
Shattuck Labs Inc. (STTK) Competitors
The following stocks are similar to Shattuck Labs based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Shattuck Labs Inc. (STTK) Financial Data
Shattuck Labs Inc. has a market capitalization of $299.31M with a P/E ratio of -3.2x. The company generates $1.00M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is -66.6% quarter-over-quarter, while maintaining an operating margin of -1,071.6% and return on equity of -57.8%.
Valuation Metrics
Market Cap
$299.31M
Enterprise Value
$206.95M
P/E Ratio
-3.2x
PEG Ratio
0.1x
Price/Sales
285.4x
Growth & Margins
Revenue Growth (YoY)
-66.6%
Gross Margin
N/A
Operating Margin
-1,071.6%
Net Margin
0.0%
EPS Growth
-66.6%
Financial Health
Cash/Price Ratio
+28.8%
Current Ratio
17.0x
Debt/Equity
2.8x
ROE
-57.8%
ROA
-33.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Shattuck Labs Inc. (STTK) Business Model
About Shattuck Labs Inc.
What They Do
Develops novel biologic therapies for cancer.
Business Model
Shattuck Labs Inc. leverages its proprietary Agonist Redirected Checkpoint (ARC) platform to develop therapies that enhance the immune response against cancer and autoimmune diseases. The company generates revenue through partnerships and collaborations to advance its clinical-stage pipeline, which includes multiple candidates targeting diverse cancer types.
Additional Information
As a biotechnology firm, Shattuck Labs is focused on innovative research and development in the immunotherapy sector, aiming to address complex health conditions with improved treatment options. Its emphasis on dual engagement of T cells and antigen-presenting cells positions it uniquely in the market, potentially providing advantages over traditional therapies.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
44
CEO
Dr. Taylor H. Schreiber M.D., Ph.D.
Country
United States
IPO Year
2020
Website
www.shattucklabs.comShattuck Labs Inc. (STTK) Latest News & Analysis
Latest News
Why Shattuck Labs Stock Soared in December
9 days ago
Quick Summary
An analyst has upgraded a stock to a "buy" recommendation, positively influencing investor sentiment.
Why It Matters
An analyst upgrade to a buy can boost stock prices and investor confidence, potentially leading to increased buying activity and market momentum.
Source: The Motley Fool
Market Sentiment:
Positive
Quick Summary
Shattuck Labs, Inc. (NASDAQ: STTK) announced the granting of inducement equity awards to a new non-executive officer on December 10, 2025, as part of its hiring process.
Why It Matters
The equity awards indicate Shattuck Labs is investing in talent to drive innovation, which could enhance its pipeline and potentially lead to increased stock value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Analyst Upgrade Boosts Shattuck On Confidence In Next-Gen Inflammatory Bowel Disease Therapy
1 month ago
Quick Summary
HC Wainwright upgraded Shattuck Labs Inc. (NASDAQ: STTK) from Neutral to Buy, setting a price target of $6, based on its lead product SL-325 for inflammatory bowel disease.
Why It Matters
The upgrade to Buy and a $6 price target signal positive sentiment and potential growth for Shattuck Labs, particularly with its promising IBD treatment.
Source: Benzinga
Market Sentiment:
Positive
Quick Summary
Shattuck Labs, Inc. (NASDAQ: STTK) will participate in investor conferences in December 2025, including the Piper Sandler 37th Annual Healthcare Conference. Presenter: Dr. Taylor Schreiber.
Why It Matters
Shattuck Labs' participation in key investor conferences signals potential developments and insights into their therapies, which could influence stock performance and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Shattuck Labs Reports Third Quarter 2025 Financial Results and Recent Business Highlights
2 months ago
Quick Summary
First participants have been dosed in a Phase 1 trial of SL-325. The company closed a $103 million private placement in August 2025 to advance this program and appointed two new executives.
Why It Matters
The Phase 1 trial progress and significant funding indicate strong potential for SL-325, while new leadership could enhance strategic direction, impacting future growth and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Shattuck Labs, Inc. (STTK) Presents at The United European Gastroenterology (UEG) Congress UEG Week 2025 Transcript
3 months ago
Quick Summary
Shattuck Labs, Inc. (NASDAQ:STTK) will participate in the UEG Week 2025 on October 8, 2025, with CEO Taylor Schreiber leading the presentation alongside analysts from Wedbush Securities.
Why It Matters
Shattuck Labs' participation in a significant medical conference may indicate potential advancements in their research, influencing investor sentiment and stock performance.
Source: Seeking Alpha
Market Sentiment:
Neutral
Frequently Asked Questions About STTK Stock
What is Shattuck Labs Inc.'s (STTK) stock forecast for 2026?
Based on our analysis of 8 Wall Street analysts, Shattuck Labs Inc. (STTK) has a median price target of $4.00. The highest price target is $6.00 and the lowest is $4.00.
Is STTK stock a good investment in 2026?
According to current analyst ratings, STTK has 4 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $4.73. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for STTK stock?
Wall Street analysts predict STTK stock could reach $4.00 in the next 12 months. This represents a -15.4% decrease from the current price of $4.73. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Shattuck Labs Inc.'s business model?
Shattuck Labs Inc. leverages its proprietary Agonist Redirected Checkpoint (ARC) platform to develop therapies that enhance the immune response against cancer and autoimmune diseases. The company generates revenue through partnerships and collaborations to advance its clinical-stage pipeline, which includes multiple candidates targeting diverse cancer types.
What is the highest forecasted price for STTK Shattuck Labs Inc.?
The highest price target for STTK is $6.00 from Joseph Pantginis at HC Wainwright & Co., which represents a 26.8% increase from the current price of $4.73.
What is the lowest forecasted price for STTK Shattuck Labs Inc.?
The lowest price target for STTK is $4.00 from Yigal Nochomovitz at Citigroup, which represents a -15.4% decrease from the current price of $4.73.
What is the overall STTK consensus from analysts for Shattuck Labs Inc.?
The overall analyst consensus for STTK is bullish. Out of 8 Wall Street analysts, 4 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $4.00.
How accurate are STTK stock price projections?
Stock price projections, including those for Shattuck Labs Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: January 15, 2026 4:26 AM UTC